Side effects control in the chemotherapy with everolimus: single-center experience
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
BACKGROUND: Renal cell carcinoma (RCC, renal cell carcinoma) accounts for 80–85% of neoplasms arising from the kidney. Everolimus, one of the selective mTOR kinase inhibitors, was recently approved for the treatment of patients with RCC.Purpose: We aimed to evaluate the frequency of severe adverse events during everolimus chemotherapy in patients with renal cell carcinoma.Patients and methods : We analyzed data from medical records of patients with renal cell carcinoma treated with everolimus from January 2010 to February 2011. All patients had histologically confirmed renal cell carcinoma. Patients received everolimus in a single daily dose of 10 mg orally, in the 30-day cycles. The severity of adverse events were determined according to the scale of Common Toxicity Criteria for Adverse Events.Results : In our database we identified 51 patients with renal cell carcinoma who underwent everolimus therapy. Median age was 57 years (95% CI: 55–66). The most common hematological severe adverse events were: anemia in 10% of the patients, and lymphopenia in 4% of the patients. There were no other hematological toxicities in the 3rd or 4th degree. Hand-foot syndrome occurred in 2% of the patients in the intensity of the third degree. Among severe metabolic complications most commonly observed adverse events were: hyperglycemia in 6% of the patients, hypercholesterolemia in 6% and hypertriglyceridemia in 4%. Dose reduction was required in 4% of the patients due to nonbacterial pneumonia.Conclusions: In our study, everolimus was safe and well tolerated with few severe side effects.
Authors and Affiliations
Ludomir Bodnar, Rafał Stec, Marta Smoter
Keywords
Related Articles
- EP ID EP53097
- DOI -
- Views 253
- Downloads 0
Paraneoplastic neurological syndrome in the course of breast cancer
Paraneoplastic neurological syndromes (PNS) are a group of rarely observed disorders, accompanying about 1% of cancer diseases. They have a typically aggressive course, leading to profound and essentially irreversible di...
Invasive fungal infection in an acute myeloid leukaemia patient
Invasive fungal infections (IFI) are one of the most severe complications of treatment in patients with acute myeloid leukaemia (AML) that are diagnosed during the myelosuppression period following intensive chemotherapy...
Pazopanib - dilemmas in kidney cancer treatment
Progress in metastatic renal cell carcinoma treatment is generally based on new registered drugs. This brings improvement of results but it also needs the choice of proper drug. The decision is especially important in in...
Płyn w worku osierdziowym zagrażający tamponadą serca u chorych onkologicznie – standardy diagnostyki i leczenia
Obecność płynu w worku osierdziowym zagrażająca tamponadą serca jest stanem bezpośredniego zagrożenia życia. Najważniejsze w takim przypadku są: rozpoznanie, ustalenie wskazań do perikardiocentezy i drenaż jamy osierdzia...
Interstitial pneumonia during treatment with rituximab
Rituximab (RTX) is a chimeric anti-CD20 antibody. It plays an important role in the treatment of B cell lymphomas and diseases of autoaggression. RTX-induced lung disease is a rare entity, which should be considered in t...